AbbVie Inc.

🇺🇸New York Stock Exchange

Articles

46
Show Summary
Show Bulletpoints
Detailed View
Bullish +65

AbbVie: Strong 2026 Outlook, Expect Dividend Increases

📉 Stock consolidated after strong Q4 2025 progress despite a recent 10% decline.

🚀 Skyrizi and Rinvoq projected to drive double-digit revenue growth in 2026.

💰 Dividend increases anticipated as Humira erosion issues are resolved.

⚠ Obesity pipeline lacks breadth; new assets or internal combination required for competitiveness.

📈 Independent author cites strong historical returns without declared conflicts of interest.

📅 Published on March 27, 2026, the article analyzes AbbVie's stock performance despite a recent 10% decline since October 2025.

🚀 Skyrizi and Rinvoq are projected to drive double-digit revenue growth in 2026, exceeding initial company guidance.

💰 With Humira erosion largely resolved, the author anticipates accelerated dividend increases in the near term.

🤝 Management is expected to pursue increased business development activity as earlier acquisitions are fully digested.

⚠️ The obesity pipeline is noted to lack breadth and differentiation without timely acquisition of new assets.

🧬 Combining existing AbbVie-295 with acquired assets is critical for enhancing competitiveness in the obesity market.

📉 AbbVie shares have consolidated following a strong commercial progress update from October 2025.

🏢 The article was written by an independent investor who leads the Growth Stock Forum without compensation.

⚖️ No conflicts of interest were declared, with no stock positions held in the mentioned companies at the time of writing.

📈 Historical portfolio performance cited includes a 137.6% increase for biotech Top Picks and a 23.2% CAGR for the core portfolio.

Bullish Signals
  • ABBV positioned for long-term growth despite market consolidation.
  • Skyrizi and Rinvoq drive double-digit 2026 revenue growth.
  • Humira erosion ended; accelerating dividend increases anticipated.
  • Business development activity increases as acquisitions digest successfully.
Risk Factors
  • AbbVie shares down 10% since October 2025 update.
  • Geopolitical headwinds threaten operational stability and revenue.
  • Obesity pipeline lacks breadth, creating competitive vulnerability.
  • Asset acquisition critical to mitigate thin pipeline risks.
Bullish Signals
  • AbbVie Inc. (ABBV) is well-positioned for long-term growth despite recent market consolidation.
  • Skyrizi and Rinvoq are expected to drive double-digit revenue growth in 2026, exceeding the company's initial guidance.
  • With Humira erosion largely behind the company, accelerating dividend increases are anticipated.
  • Increased business development activity is expected as previous acquisitions continue to be successfully digested.
Risk Factors
  • Shares of AbbVie Inc. (ABBV) are down approximately 10% since the author's October 2025 update, indicating recent market weakness despite the bullish outlook.
  • The company faces near-term geopolitical headwinds that could impact operational stability and revenue realization in the upcoming fiscal year.
  • AbbVie’s obesity pipeline lacks breadth and differentiation, creating a significant competitive vulnerability as the company seeks to enhance competitiveness with ABBV-295.
  • Timely acquisition of assets is critical to mitigate risks related to the limited pipeline depth in the obesity market segment.
Neutral 0

Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV)

📈 Piper Sandler analyst reiterated a "Buy" rating with a $299 price target.

💰 Quarterly revenue hit $16.62B and net profit reached $1.82B.

⚖️ Insider sentiment remains negative following significant share sales by executives.

👤 Analyst David Amsellem boasts a 50.9% historical success rate on picks.

- 📈 Piper Sandler analyst David Amsellem reiterated a "Buy" rating on AbbVie with a price target of $299.00.

- 💰 The company reported quarterly revenue of $16.62 billion and net profit of $1.82 billion for the quarter ending December 31.

- 📊 This represents significant growth from last year, which saw $15.1 billion in revenue and a GAAP net loss of $22 million.

- 🧑‍💼 Corporate insider sentiment is currently negative due to increased selling activity among 41 insiders over the past quarter.

- 💸 Specifically, SVP David Ryan Purdue sold 5,230 shares worth approximately $1.22 million earlier this month.

- ⚖️ Other analyst coverage includes a "Buy" from TipRanks and Google's Drug Manufacturers team, though Anthropic maintained a "Hold."

- 👤 Amsellem covers the Healthcare sector with a historical average return of 6.5% and a 50.90% success rate on recommended stocks.

- ⚾ AbbVie was recently named the Official Pharmaceutical Partner of Major League Baseball in a separate announcement.

Bullish Signals
  • Piper Sandler analysts reiterated a 'Buy' rating on AbbVie (ABBV), demonstrating continued institutional confidence in the stock.
  • David Amsellem of Piper Sandler set a price target of $299.00, providing a clear upside potential for investors following his analysis.
  • AbbVie reported strong quarterly revenue of $16.62 billion based on the quarter ending December 31, representing growth from the prior year's $15.1 billion.
  • The company turned its profit situation around significantly, reporting a net profit of $1.82 billion compared to a GAAP net loss of $22 million last year.
  • Amsellem has a historical track record with an average return of 6.5% and a 50.90% success rate on his recommended stocks.
  • AbbVie was recognized as the Official Pharmaceutical Partner of Major League Baseball, expanding its brand visibility and partnerships.
Risk Factors
  • Corporate insider sentiment is negative as over the past quarter, 41 insiders have increased their share sales compared to earlier in the year.
  • David Ryan Purdue, SVP and Controller of AbbVie (ABBV), recently sold 5,230 shares worth $1.22 million, signaling a lack of confidence from top-level executives.
  • AbbVie is facing mixed analyst sentiment, with TipRanks noting that while Piper Sandler maintains a Buy rating, Anthropic has reiterated a Hold rating on the stock.
  • The recent surge in insider selling is explicitly noted as spooking investors, causing the AbbVie stock to slide in price.
Somewhat Bullish +50

Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

📉 Stock dropped 6.6% this week despite strong long-term gains.

💰 DCF model suggests current price is ~44% below intrinsic value.

⚠️ P/E ratio of 86.68x significantly exceeds peer and industry averages.

📉 AbbVie's stock price has recently weakened, declining 6.6% over the past week and 10.5% year-to-date while trading around US$205.20.

📊 Despite recent declines, the stock maintains a long-term track record with 5-year returns of 132.7% and a 44.5% gain over three years.

🧬 Investors are closely monitoring AbbVie due to ongoing attention on its product portfolio and competitive position within the large US pharmaceutical sector.

📊 Simply Wall St assigns AbbVie a value score of 3 out of 6, indicating it passes as undervalued on half of their six screening checks.

💰 A Discounted Cash Flow (DCF) model estimates an intrinsic value of US$366.91, suggesting the stock is approximately 44.1% below that DCF estimate.

📈 The DCF analysis specifically uses a Two-Stage Free Cash Flow to Equity approach with explicit analyst forecasts extending out to 2030.

💹 AbbVie currently trades at a P/E ratio of 86.68x, which is significantly higher than the peer average of 22.56x and industry average of 16.90x.

⚠️ Based on a proprietary Fair Ratio of 38.23x, the company's current valuation screens as overvalued compared to its earnings growth profile and risk factors.

📖 Simply Wall St suggests using "Narratives" to build custom fair value stories that align forecasts with specific views on revenue and earnings.

💡 One community narrative example estimates a fair value near US$253 using a 17.5x forward P/E multiplied by projected 2026 EPS of US$14.47.

🔍 Another investor perspective estimates a fair value around US$249 based on a 24.0x P/E applied to 2029 earnings forecasts.

⚠️ The article states that its analysis is general in nature, relies on historical data and analyst forecasts, and does not constitute financial advice.

🛑 Simply Wall St explicitly notes that their methodology may not factor in the latest price-sensitive announcements or specific qualitative material.

Bullish Signals
  • Although recent stock weakness has pushed the share price down, AbbVie still delivers a strong long-term performance with returns of 44.5% over the past three years and 132.7% over five years.
  • Based on a Discounted Cash Flow model, AbbVie trades at approximately 44.1% below its estimated intrinsic value of US$366.91, signaling significant upside potential.
  • The company generated robust free cash flow of around US$18.0b in the latest twelve months, with projections reaching US$31.5b by 2030.
  • Investors can utilize Simply Wall St's automated Narrative tools to track evolving forecasts for revenue, earnings, and fair value against a current market price of around US$205.
Risk Factors
  • AbbVie's share price has declined significantly, falling 6.6% over the past week, 8.7% over the past month, and 10.5% year to date, resulting in a current price of approximately US$205.
  • The stock's one-year return of 5.3% is lagging behind its peers, raising concerns about relative performance despite strong historical growth over longer periods.
  • On a P/E basis, AbbVie trades at a multiple of 86.68x, which sits well above Simply Wall St's Fair Ratio estimate of 38.23x and the industry average of 16.90x, suggesting significant overvaluation.
  • Simply Wall St's valuation model yields a score of only 3 out of 6, indicating that the company fails to screen as undervalued on the majority of key checks.
Neutral 0

AbbVie (NYSE:ABBV) Expands Awareness And Psychedelic Research Russell 1000

🏛 AbbVie expands psychedelic research within the Russell 1000 index.

💊 Healthcare evolves through scientific innovation and therapeutic diversification.

🔒 Access full content via free account registration or form submission.

✅ Registration confirms consent for marketing communications from Kalkine Media.

🏛️ AbbVie (NYSE:ABBV) is expanding its awareness and psychedelic research initiatives within the Russell 1000 index context.

💊 The healthcare sector is evolving through scientific research, public engagement, and therapeutic diversification.

⚡ A combination of established pharmaceutical capabilities and new research avenues reflects this blend.

🔒 Readers must log in, create a free account, or fill out a form to access the full article content.

✅ By submitting details, users confirm consent for Kalkine Media representatives to contact them regarding marketing offers and discussions.

📞 Contact methods include email and phone calls made by Kalkine group's telemarketing entities on behalf of the publisher.

Bullish Signals
  • No meaningful points found.
  • Input array is empty.
  • Unable to condense content.
  • Missing data for processing.
  • List contains no items.
Bullish Signals
Risk Factors
  • The provided article is a promotional landing page and not substantive financial news; it contains no actual negative points, risks, or data about AbbVie.
  • The text lists unrelated positive headlines for competitors like Transocean (NYSE:RIG) and AstraZeneca (NYSE:AZN), but offers no information on AbbVie's specific operational or financial challenges.
Somewhat Bullish +45

LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?

📊 Eli Lilly GLP-1 drugs generated $36.5B in 2025 sales representing over half its revenue.

💼 AbbVie's Skyrizi and Rinvoq hit $26B combined sales, exceeding 2027 guidance for 2026.

🚀 Both companies expect key drug growth despite price declines and legacy product revenue drops.

⚡ Lilly launches oral GLP-1 in Q2 2026; AbbVie acquired $5B+ assets to expand pipelines.

⚖ Strong balance sheets support both firms diversifying into neuroscience, oncology, and cardiovascular markets.

🔍 The article compares Eli Lilly (LLY) and AbbVie (ABBV) as top contenders for investment upside in 2026.

💊 Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $36.5 billion in 2025 sales, representing over half of its total revenue.

🚀 Both companies' GLP-1 or other key drug sales are expected to continue growing into 2026 despite potential market headwinds.

💼 AbbVie successfully navigated Humira's patent loss with Skyrizi and Rinvoq, which generated $26 billion in 2025 combined sales.

📈 Lilly expects its approved pipeline drugs including orforglipron to drive further growth and offset declining legacy product revenues.

🗓️ Lilly plans to launch its oral GLP-1 pill orforglipron in the US during the second quarter of 2026 to compete with Novo Nordisk's recent oral Wegovy.

⚠️ Price declines for Lilly's products in the US and rising competition are expected to impact top-line growth by a low to mid-teens percentage in 2026.

💰 AbbVie expects combined Skyrizi and Rinvoq sales to exceed $31 billion in 2026, surpassing its long-term guidance target for 2027.

🧠 AbbVie's neuroscience portfolio drove revenue growth with nearly $20% increase to $10.8 billion in 2025 led by Botox and migraine drugs.

⚖️ Lilly is diversifying beyond obesity into cardiovascular, oncology, and neuroscience areas through M&A deals announced in 2025.

🏥 AbbVie acquired over $5 billion worth of early-stage assets in 2025 to bolster its immunology, oncology, and neuroscience pipelines.

📉 Both companies face legacy product declines but maintain strong balance sheets and global reach across key therapeutic areas.

🧬 Lilly is developing retatrutide, a triple-acting incretin for obesity and diabetes, alongside other indications in late-stage studies.

⚙️ AbbVie's oncology segment grew 1.5% year-over-year to $6.6 billion in 2025 despite some decline in key product Imbruvica sales.

🌍 Both firms have extensive global operations with strong presence in immunology, oncology, and neuroscience markets.

Bullish Signals
  • Skyrizi and Rinvoq generated $26.0 billion in 2025 sales with over 40% growth.
  • Combined Skyrizi/Rinvoq 2026 sales expected to exceed $31 billion targets.
  • Neuroscience portfolio sales surged nearly 20% to $10.8 billion in 2025.
  • On oncology generated $6.6 billion in 2025, up 1.5% year over year.
  • AbbVie invested over $5 billion in 2025 acquisitions for long-term pipeline growth.
  • Lilly's new drugs including Mounjaro and Ebglyss will drive 2026 sales.
  • Multiple Lilly therapies like Kisunla and Omvoh recently received regulatory approvals.
  • Lilly's orforglipron oral GLP-1 launches Q2 2026 as injectable alternative.
Risk Factors
  • Declining US drug prices expected to drag growth by low-mid teens in 2026.
  • Late-cycle sales of Trulicity, Taltz, and Verzenio projected flat or down in 2026.
  • Novo Nordisk's oral Wegovy approval may erode Lilly market share before forglipron launches Q2 2026.
  • Rising GLP-1 competition threatens growth trajectories for Mounjaro and Zepbound.
  • AbbVie expects $31B combined 2026 sales to miss both own and 2027 guidance.
Bullish Signals
  • AbbVie successfully navigated Humira loss of exclusivity by launching two highly successful immunology medicines, Skyrizi and Rinvoq, which generated combined sales of $26.0 billion in 2025 with year-over-year growth of more than 40%.
  • In 2026, AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion, exceeding its long-term guidance targets and signaling strong product momentum.
  • AbbVie's neuroscience portfolio contributed robust growth with sales increasing almost 20% to $10.8 billion in 2025, driven by Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta.
  • The oncology segment generated combined revenues of $6.6 billion in 2025, up 1.5% year over year, supported by higher sales of Venclexta and new drugs Elahere and Epkinly.
  • AbbVie has invested more than $5 billion in 2025 on acquisitions to bolster its early-stage pipeline in immunology, oncology, and neuroscience areas for long-term growth.
  • Eli Lilly expects its new drug portfolio including Mounjaro, Zepbound, Ebglyss, Jaypirca, Kisunla, Omvoh, and Inluriyo to drive sales growth in 2026.
  • Lilly secured approvals for several new therapies such as Omvoh, Jaypirca, Ebglyss and Kisunla over the past few years, all contributing to revenue expansion.
  • Lilly's once-daily oral GLP-1 small molecule orforglipron is expected to launch in the United States during the second quarter of 2026, offering a convenient alternative to injectable treatments.
  • AbbVie and Lilly both maintain strong R&D pipelines, significant market capitalizations, and extensive global reach across key therapeutic areas like immunology, oncology, and neuroscience.
Risk Factors
  • Lilly faces a significant headwind from declining product prices in the United States, with price erosion expected to continue dragging on top-line growth by a low to mid-teens percentage in 2026.
  • Sales of late-life cycle products including Trulicity, Taltz, and Verzenio are projected to be flat or decline in 2026 as competition intensifies.
  • Novo Nordisk's approval of an oral version of Wegovy in December 2025 gives the rival first-to-market advantage, potentially eroding Lilly's market share and revenues before its own oral obesity pill, orforglipron, launches in the second quarter of 2026.
  • Rising competition in the GLP-1 diabetes and obesity market is identified as a key headwind that could impact growth trajectories for Lilly's blockbuster Mounjaro and Zepbound.
  • AbbVie may face revenue challenges despite strong Skyrizi and Rinvoq sales, as it expects 2026 combined sales of $31 billion to fall short of its own long-term guidance, which also stands at $31 billion for 2027.
Bullish +75

Market Downturn: 2 Stocks to Buy and Hold Through Any Storm

⚠ Defensive pharma and tech stocks are highlighted for stability during market volatility.

💊💻 AbbVie offers patent diversification while Microsoft provides reliable recurring revenue from productivity tools.

🏆 The Motley Fool's Stock Advisor has historically delivered massive returns significantly outperforming the S&P 500.

📉 Markets face volatility due to geopolitical tensions and tariff uncertainty, prompting investors to seek defensive assets.

💊 AbbVie is highlighted as a resilient pharmaceutical stock with a strong portfolio in chronic autoimmune conditions and cancer therapies.

🛡️ Pharma stocks are generally considered defensive because demand for essential medicines remains stable during economic slowdowns.

🔄 AbbVie has a deep product pipeline that helps mitigate risks associated with patent cliff expiration.

👑 The company is a "Dividend King," having increased its dividend payouts for 50 consecutive years, which helps smooth investor losses during downturns.

💻 Microsoft is presented as a defensive tech stock due to its entrenched products like Office used daily by individuals and businesses.

☁️ While Azure is a growth engine, the company maintains consistent revenue from productivity tools even if clients tighten budgets in a recession.

⭐ Microsoft holds an Aaa credit rating, which is higher than that of the U.S. government, signaling rock-solid financial health.

📈 Investors may buy Microsoft at a discount during downturns, expecting it to recover and deliver superior long-term returns as before.

⚠️ AbbVie was notably excluded from The Motley Fool's current list of top 10 stocks recommended by the Stock Advisor team.

🏆 The Stock Advisor report highlights massive historical returns for past picks like Netflix (52x return) and Nvidia (113x return).

📊 The average total return for the Stock Advisor service is reported at 952%, significantly outperforming the S&P 500's 191%.

⏳ All Stock Advisor returns cited are noted as of March 11, 2026.

🧑‍💼 Prosper Junior Bakiny holds no position in the mentioned stocks, while The Motley Fool itself recommends AbbVie and Microsoft.

Bullish Signals
  • AbbVie (NYSE: ABBV) is a 'Dividend King' with 50 years of payout increases.
  • Its portfolio targets resilient chronic autoimmune and cancer markets.
  • A deep pipeline offers strategies to navigate the patent cliff.
  • As a defensive stock, it generates consistent revenue during volatility.
Risk Factors
  • Equity market volatility fears persist amid geopolitical tensions and tariff uncertainty.
  • AbbVie excluded from Motley Fool's top 10 stocks list.
  • Dividends may not offset losses during severe market crashes.
  • Azure growth could moderate if clients tighten recession budgets.
  • Microsoft may fall sharply with the broader market in a downturn.
  • AbbVie prescription volumes may soften during challenging economic periods.
Bullish Signals
  • AbbVie (NYSE: ABBV) is highlighted as a 'Dividend King' with 50 straight years of payout increases, providing income stability during market downturns.
  • The company possesses a vast pharmaceutical portfolio focused on chronic autoimmune conditions and cancer, sectors which tend to remain resilient even when prescription volumes soften.
  • AbbVie has a deep pipeline that allows it to develop and launch new products, offering a strategic way to navigate the patent cliff.
  • As a defensive stock, AbbVie is positioned to generate consistent revenue and earnings even during severe economic problems or market volatility.
  • The Motley Fool has identified AbbVie as a top stock for investors to prepare for a market downturn, specifically noting its defensive nature against cyclical exposure.
Risk Factors
  • Equity markets have been volatile this year, with some fear the stock market could take a turn for the worse by the end of the year amid geopolitical tensions and lingering tariff-related uncertainty.
  • The article explicitly states that AbbVie was not included in the Motley Fool Stock Advisor's list of 10 best stocks to buy now, potentially implying it is not among their top tier of high-conviction picks.
  • While AbbVie's dividend status as a Dividend King is noted as positive, dividends may not be sufficient to offset losses if the company faces severe challenges or market crashes that impact its payout ability.
  • Microsoft's Azure segment could see growth moderate if clients tighten budgets during a recession, indicating potential downside pressure on its primary growth engine.
  • The article acknowledges that Microsoft is unlikely to emerge entirely unscathed from an economic downturn, with the possibility of falling sharply along with the rest of the market before recovering.
  • Prescription volumes for AbbVie may soften during challenging periods, which could impact consistent revenue generation despite strong demand in specific therapeutic areas.